ＳＢＩホールディングス（8473） – ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED MARCH 31, 2022

SBI HOLDINGS, INC. (Incorporated in Japan with limited liability) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED MARCH 31, 2022 The board of directors (the “Directors”) of SBI HOLDINGS, INC. (the “Company”) is pleased to announce the consolidated results of the Company and its subsidiaries (collectively the “Group”) for the year ended March 31, 2022. (Amounts are rounded to the nearest million Japanese yen) 1. Consolidated Financial Results (1) Consolidated Operating Results (Percentages represent year-on-year changes) (Note) Share of results of associates Fiscal year ended March 31, 2022: 6,822 million yen Fiscal year ended March 31, 2021: 9,458 million yen 1 Millions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%Fiscal year endedMarch 31, 2022763,61841.1412,724194.0355,724264.8366,854352.4Fiscal year endedMarch 31, 2021541,14547.0140,380113.397,512116.781,098116.3RevenueProfit before incometax expenseProfit for the yearProfit attributable toowners of theCompanyBasic earnings per shareattributable to owners ofthe CompanyDiluted earnings per shareattributable to owners ofthe CompanyMillions ofyen%YenYenFiscal year endedMarch 31, 2022380,820211.71,498.551,285.90Fiscal year endedMarch 31, 2021122,187479.3339.78296.92Total comprehensiveincomeRatio of profit to equityattributable to owners of theCompanyRatio of profit beforeincome tax expenseto total assetsRatio of operating incometo operating revenue%%%Fiscal year endedMarch 31, 202249.43.354.0Fiscal year endedMarch 31, 202116.02.225.9 (2) Consolidated Financial Position (3) Consolidated Cash Flows 2. Dividends (Note) Fiscal year ending March 31, 2023 forecast is to be determined. 3. Total number of shares outstanding (Common stock) The Group prepared the consolidated financial statements in accordance with IFRSs. 2 Total assetsTotal equityEquity attributableto owners ofthe CompanyRatio of equityattributable toowners ofthe Company tototal assetsEquity per shareattributable toowners of theCompanyMillions of yenMillions of yenMillions of yen%YenMarch 31, 202217,838,2001,583,258924,6035.23,770.84March 31, 20217,208,572717,095562,1167.82,297.87Operating activitiesInvesting activitiesFinancing activitiesCash and cashequivalents at theend of the yearMillions of yenMillions of yenMillions of yenMillions of yenFiscal year endedMarch 31, 2022(314,046)1,838,517163,3022,499,370Fiscal year endedMarch 31, 2021(178,403)(82,071)210,822802,702(Declared date)End of1st QEnd of2nd QEnd of3rd QYear-endFull yearYenYenYenYenYenMillionsof yen%%Fiscal year endedMarch 31, 2021－20.00－100.00120.0029,32435.35.6Fiscal year endedMarch 31, 2022－30.00－120.00150.0036,77010.04.9Fiscal Year endingMarch 31, 2023(forecast)　(Note)－－－－－－Ratio ofdividend toequityattributableto owners ofthe Company(cons.)Payout ratio(cons.)Totaldividend(annual)Dividend per share(1)Number of shares outstanding (including:March 31, 2022:245,220,890sharestreasury stock)March 31, 2021:244,639,390shares(2)Number of treasury stock:March 31, 2022:22,486sharesMarch 31, 2021:15,084shares(3)Average number of shares outstanding:Year ended March 31, 2022:244,805,985sharesYear ended March 31, 2021:238,676,048shares(Reference Information) Non-consolidated Financial Results (1) Non-consolidated Operating Results (Percentages represent year-on-year changes) (2) Non-consolidated Financial Position (Note) Shareholders’ equity Fiscal year ended March 31, 2022: 385,297 million yen Fiscal year ended March 31, 2021: 391,107 million yen The non-consolidated financial results were prepared in accordance with JGAAP. This financial summary is not subject to audit. 3 Millions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%Fiscal year endedMarch 31, 202277,081(13.3)50,226(29.0)30,493(56.2)36,69456.2Fiscal year endedMarch 31, 202188,901178.470,786446.769,573632.523,499114.9Operating incomeOrdinary incomeNet incomeNet salesNet incomeper shareDiluted net incomeper shareYenYenFiscal year endedMarch 31, 2022149.89127.18Fiscal year endedMarch 31, 202198.4684.11Total assetsNet assetsRatio of shareholder’sequity to total assetsNet assetsper shareMillions of yenMillions of yen%YenMarch 31, 20221,278,754387,23830.11,571.37March 31, 20211,085,970392,48536.01,598.811. BUSINESS RESULTS (1) Overview of Business Results for the Fiscal Year The Group’s consolidated results of operations for the fiscal year ended March 31, 2022 were as follows. Revenue was ¥763,618 million yen (up ¥222,473 million, or 41.1% year-on-year), profit before income tax expense was ¥412,724 million (up ¥272,344 million, or 194.0% year-on-year), and profit attributable to owners of the Company was ¥366,854 million (up ¥285,756 million, or 352.4% year-on-year). The increase in revenue was mainly due to an increase in “Income arising from financial assets measured at FVTPL” recognized in investments in venture companies and an increase in “Income arising from financial assets measured at amortized cost” due to the inclusion of Shinsei Bank, Limited beginning with the nine months ended December 31, 2021. The increase in profit before income tax expense was mainly due to the inclusion of Shinsei Bank, Limited, resulting in a gain on bargain purchase of 263,847 million yen. The results of operations for each reporting segment of the Group for the fiscal year ended March 31, 2022 were as follows. SBI Estate Finance Co., Ltd. and SBI Guarantee Co., Ltd., which were included in the Asset Management Business until the previous reporting period, are now included in the Financial Services Business beginning with the six months ended September 30, 2021. Consequently, segment information for the year ended March 31, 2021, is restated in accordance with the new basis of segmentation. Also, Shinsei Bank, Limited is included in the Financial Services Business beginning with the nine months ended December 31, 2021. (% represents year-on-year changes) (Financial Services Business) The Financial Services Business consists of a wide range of finance-related business, including securities brokerage business, banking services business and life, property and casualty insurance business. The results of operations of the Financial Services Business for the fiscal year ended March 31, 2022 were as follows. Revenue increased 26.1% year-on-year to ¥396,179 million, and profit before income tax expense increased 227.5% to ¥282,924 million. This was mainly due to the inclusion of Shinsei Bank, Limited in the Financial Services Business beginning with the nine months ended December 31, 2021, resulting in a gain on bargain purchase of 263,847 million yen. 4 Fiscal yearendedMarch 31,2021Fiscal yearendedMarch 31,2021Millions ofYenMillions ofYen%Millions ofYenMillions ofYen%Financial Services Business314,159396,17926.186,386282,924227.5Asset Management Business205,871317,83154.484,188165,96297.1Biotechnology, Healthcare &Medical Informatics Business5,6279,92076.3(8,630)(11,845)－　Total525,657723,93037.7161,944437,041169.9Others21,73344,293103.8(10,562)(11,990)－Elimination or Corporate(6,245)(4,605)－(11,002)(12,327)－Consolidated Total541,145763,61841.1140,380412,724194.0RevenueProfit before income tax expenseFiscal year endedMarch 31, 2022Fiscal year endedMarch 31, 2022(Asset Management Business) The Asset Management Business primarily consists of fund management and investment in Internet technology, fintech, blockchain, finance, and biotechnology-related venture companies in Japan and overseas, financial services business overseas, and asset management services business which provides financial products information. The results of operations of the Asset Management Business for the fiscal year ended March 31, 2022 were as follows. Revenue increased 54.4% year-on-year to ¥317,831 million, and profit before income tax expense increased 97.1% year-on-year to ¥165,962 million. This was mainly due to an increase in “Income arising from financial assets measured at FVTPL” recognized in investments in companies. (Biotechnology, Healthcare & Medical Informatics Business) The Biotechnology, Healthcare & Medical Informatics Business represents development and distribution of pharmaceutical products, health foods, and cosmetics with 5-aminolevulinic acid (ALA*), a kind of amino acid which exists in vivo, research and development of antibody drugs and nucleic acid medicine in the field of cancer and immunology, the digitization of medical and health information, providing solutions and services that promote and the use of medical big data, and medical finance. The results of operations of the Biotechnology, Healthcare & Medical Informatics Business for the fiscal year ended March 31, 2022 were as follows. Revenue increased 76.3% year-on-year to ¥9,920 million, and loss before income tax expense amounted to ¥11,845 million for the fiscal year ended March 31, 2022 (¥8,630 million of loss before income tax expense for the fiscal year ended March 31, 2021). * Five-aminolevulinic acid (ALA) is an amino acid generated by mitochondria in the human body and an important substance used to produce heme or cytochrome, proteins to generate energy. The production of ALA in the human body decreases with age. ALA is included in food products, including slops of distilled spirits, red wine, and Asian ginseng. ALA is also known as a chloroplastic substance in plants. (2) Overview of Financial Conditions for the Fiscal Year As at March 31, 2022, total assets amounted to ¥17,838,200 million and increased by ¥10,629,628 million from total assets of ¥7,208,572 million as at March 31, 2021. The Group’s equity increased by ¥866,163 million to ¥1,583,258 million from the fiscal year ended March 31, 2021. As at March 31, 2022, the Group’s cash and cash equivalents amounted to ¥2,499,370 million and increased by ¥1,696,668 million from that of ¥802,702 million as at March 31, 2021. The changes of cash flows for each activity and the reasons for changes are as follows: (Operating Cash Flows) Cash flows from operating activities amounted to ¥314,046 million in net cash outflows (¥178,403 million in net cash outflows for the year ended March 31, 2021). The net cash outflows were primarily due to a ¥373,371 million cash outflow from an increase in trade and other accounts receivables, a ¥263,847 million cash outflow from a gain on bargain purchase, a ¥165,985 million cash outflow from a decrease in payables under securities lending transactions, and a ¥164,644 million cash outflow from an increase in operational investment securities, despite a ¥412,724 million cash inflow from a profit before income tax expense, and a ¥184,308 million cash inflow from an increase in customer deposits for banking business. (Investing Cash Flows) Cash flows from investing activities amounted to ¥1,838,517 million in net cash inflows (¥82,071 million in net cash outflows for the year ended March 31, 2021). The net cash inflows were primarily due to a ¥1,734,730 million cash inflow from an acquisition of subsidiaries, net of cash and cash equivalents acquired. 5 (Financing Cash Flows) Cash flows from financing activities amounted to ¥163,302 million in net cash inflows (¥210,822 million in net cash inflows for the year ended March 31, 2021). The net cash inflows were primarily due to a ¥541,125 million cash inflow from proceeds from issuance of bonds payable, despite a ¥257,418 million cash outflow from a decrease in short term loans payable, and a ¥158,994 million cash outflow from a redemption of bonds payable. 2. THE BASIC CONCEPT REGARDING SELECTION OF ACCOUNTING STANDARDS The Group applied IFRS from the fiscal year ended March 31, 2013 in order to improve the international comparability of financial information in the capital markets. 6 3. CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (1) Consolidated Statement of Financial Position 7 As at March 31,2021As at March 31,2022Millions of YenMillions of YenAssetsCash and cash equivalents802,7022,499,370Trade and other accounts receivable1,183,8968,399,588Assets related to securities businessCash segregated as deposits2,292,7432,361,620Margin transaction assets972,573929,730Other assets related to securities business631,305615,967Total assets related to securities business3,896,6213,907,317Other financial assets 58,715471,607Operational investment securities528,154607,802Other investment securities (includes ¥247,299 million pledged ascollateral as at March 31, 2022)209,5451,076,780Investments accounted for using the equity method103,807129,141Investment properties-34,868Property and equipment64,290123,737Intangible assets225,607293,086Other assets123,071277,016Deferred tax assets12,16417,888Total assets7,208,57217,838,200LiabilitiesBonds and loans payable1,394,1373,364,860Trade and other accounts payable189,729487,846Liabilities related to securities businessMargin transaction liabilities269,152254,345Loans payable secured by securities 602,921599,159Deposits from customers1,277,8081,375,599Guarantee deposits received961,651997,678Other liabilities related to securities business410,270449,551Total liabilities related to securities business3,521,8023,676,332Customer deposits for banking business1,042,1327,673,324Insurance contract liabilities150,123155,216Income tax payable20,12513,351Other financial liabilities30,333538,512Other liabilities107,301287,577Deferred tax liabilities35,79557,924Total liabilities6,491,47716,254,942EquityCapital stock98,71199,312Capital surplus147,753151,390Treasury stock(40)(62)Other components of equity18,19742,865Retained earnings297,495631,098Equity attributable to owners of the Company562,116924,603Non-controlling interests 154,979658,655Total equity717,0951,583,258Total liabilities and equity7,208,57217,838,200(2) Consolidated Statements of Income and Comprehensive Income Consolidated Statement of Income 8 Fiscal year endedMarch 31, 2021Fiscal year endedMarch 31, 2022Millions of YenMillions of YenRevenue (includes ¥143,364 million and ¥209,419 million ofinterest income)541,145763,618ExpenseFinancial cost associated with financial income(26,773)(33,603)Provision for credit losses(41,147)(99,489)Operating cost(142,519)(221,822)Selling, general and administrative expenses(163,326)(229,834)Other financial cost(5,803)(8,555)Other expenses(30,655)(28,260)Total expense(410,223)(621,563)Gain on bargain purchase-263,847Share of the profit of associates and joint venturesaccounted for using the equity method9,4586,822Profit before income tax expense140,380412,724Income tax expense(42,868)(57,000)Profit for the year97,512355,724Profit for the year attributable toOwners of the Company81,098366,854Non-controlling interests16,414(11,130)Profit for the year97,512355,724Earnings per share attributable to owners of theCompanyBasic (Yen)339.781,498.55Diluted (Yen)296.921,285.90Consolidated Statement of Comprehensive Income 9 Fiscal year endedMarch 31, 2021Fiscal year endedMarch 31, 2022Millions of YenMillions of YenProfit for the year97,512355,724Other comprehensive incomeItems that will not be reclassified subsequently toprofit or lossEquity instruments measured at FVTOCI(18)(493)Changes in own credit risk on financial liabilities-234Remeasurement of defined benefit plans-(1,091)Share of other comprehensive income ofassociates and joint ventures accounted forusing the equity method10913091(1,220)Items that may be reclassified subsequently toprofit or lossDebt instruments measured at FVTOCI(168)(4,692)Currency translation differences23,87130,241Share of other comprehensive income ofassociates and joint ventures accounted forusing the equity method88176724,58426,316Other comprehensive income, net of tax24,67525,096Total comprehensive income122,187380,820Total comprehensive income attributable toOwners of the Company105,680390,080Non-controlling interests16,507(9,260)Total comprehensive income122,187380,820(3) Consolidated Statement of Changes in Equity 10 CapitalstockCapitalsurplusTreasurystockOthercomponentsof equityRetainedearningsTotalMillionsof YenMillionsof YenMillionsof YenMillionsof YenMillionsof YenMillionsof YenMillionsof YenMillionsof YenAs at April 1, 202092,018139,993(13,874)(6,385)239,724451,476142,223593,699Profit for the year—-81,09881,09816,41497,512Other comprehensiveincome—24,582-24,5829324,675Total comprehensiveincome—24,58281,098105,68016,507122,187Issuance of new shares2,6522,271—4,923-4,923Issuance of convertiblebonds-2,756—2,756-2,756Conversion of convertiblebonds4,041(484)12,805–16,362-16,362Change in scope ofconsolidation——(9,788)(9,788)Dividends paid—-(23,327)(23,327)(15,018)(38,345)Treasury sharespurchased–(39)–(39)-(39)Treasury shares sold-(378)1,068–690-690Share-based paymenttransactions-799—799(5)794Changes of interests insubsidiaries without losingcontrol-2,796—2,79621,06023,856As at March 31, 202198,711147,753(40)18,197297,495562,116154,979717,095Profit for the year—-366,854366,854(11,130)355,724Other comprehensiveincome—23,226-23,2261,87025,096Total comprehensiveincome—23,226366,854390,080(9,260)380,820Issuance of new shares601482—1,083-1,083Change in scope ofconsolidation——496,303496,303Dividends paid—-(31,809)(31,809)(15,001)(46,810)Treasury sharespurchased–(23)–(23)-(23)Treasury shares sold-01–1-1Share-based paymenttransactions-682—682(731)(49)Changes of interests insubsidiaries withoutlosing control-2,473—2,47332,36534,838Transfer—1,442(1,442)—As at March 31, 202299,312151,390(62)42,865631,098924,603658,6551,583,258TotalequityNon-controllinginterestsAttributable to owners of the Company(4) Consolidated Statement of Cash flows 11 Fiscal year endedMarch 31, 2021Fiscal year endedMarch 31, 2022Millions of YenMillions of YenCash flows from operating activitiesProfit before income tax expense140,380412,724Depreciation and amortization24,29132,207Gain on bargain purchase-(263,847)Share of profits of associates and joint ventures accountedfor using the equity method(9,458)(6,822)Interest and dividend income(150,325)(222,612)Interest expense32,57342,553Increase in operational investment securities(131,448)(164,644)Increase in trade and other accounts receivables(246,508)(373,371)Increase in trade and other accounts payable88,23725,653(Increase) decrease in assets/liabilities related to securitiesbusiness(221,904)145,057Increase in customer deposits for banking business220,081184,308Decrease in bonds and loans payable in banking business-(26,148)Decrease in payables under securities lendingtransactions-(165,985)Others(17,223)(69,182)Subtotal(271,304)(450,109)Interest and dividend income received145,959218,586Interest paid(29,281)(37,551)Income taxes paid(23,777)(44,972)Net cash used in operating activities(178,403)(314,046)Cash flows from investing activitiesPurchases of intangible assets(15,419)(25,965)Purchases of investment securities(77,392)(321,150)Proceeds from sales or redemption of investmentsecurities40,735512,343Acquisition of subsidiaries, net of cash and cashequivalents acquired(8,026)1,734,730Proceeds from sales of subsidiaries, net of cash and cashequivalents disposed of-718Payments of loans receivable(70,172)(95,491)Collection of loans receivable49,86065,181Others(1,657)(31,849)Net cash (used in) generated from investing activities(82,071)1,838,517 12 Fiscal year endedMarch 31, 2021Fiscal year endedMarch 31, 2022Millions of YenMillions of YenCash flows from financing activitiesIncrease (decrease) in short term loans payable69,808(257,418)Proceeds from long-term loans payable54,936154,290Repayment of long-term loans payable(21,953)(84,387)Proceeds from issuance of bonds payable228,124541,125Redemption of bonds payable(112,576)(158,994)Proceeds from issuance of shares4,923693Proceeds from stock issuance to non-controlling interests6,3565,008Contributions from non-controlling interests in consolidatedinvestment funds15,57227,262Cash dividends paid(23,313)(31,795)Cash dividends paid to non-controlling interests(763)(1,372)Distributions to non-controlling interests in consolidatedinvestment funds(14,243)(13,610)Purchase of treasury stock(39)(23)Proceeds from sale of interests in subsidiaries to non-controlling interests9,2233,182Payments for purchase of interests in subsidiaries fromnon-controlling interests(155)(11,507)Others(5,078)(9,152)Net cash generated from financing activities210,822163,302Net (decrease) increase in cash and cash equivalents(49,652)1,687,773Cash and cash equivalents at the beginning of the year843,755802,702Effect of changes in exchange rate on cash and cashequivalents8,5998,895Cash and cash equivalents at the end of the year802,7022,499,370(5) Notes to Consolidated Financial Statements 1. Segment Information The Group engages in a wide range of business activities, primarily online financial service businesses and investment activities in Japan and overseas. Based on the similarities or economic characteristics of business or nature of services, “Financial Services Business”, “Asset Management Business”, and “Biotechnology, Healthcare & Medical Informatics Business”, which is anticipated to be a growth industry, are determined as reportable segments. The reportable segments of the Group represent businesses activities for which separate financial information of the Group’s components is available and reviewed regularly by the board of directors for the purpose of allocation of financial resources and performance evaluation. The following is a description of business activities for the reporting segments. “Financial Services Business” The Financial Services Business consists of a wide range of finance-related business, including securities brokerage business, banking services business, and life, property and casualty insurance business. “Asset Management Business” The Asset Management Business primarily consists of fund management and investment in Internet technology, fintech, blockchain, finance, and biotechnology-related venture companies in Japan and overseas, financial services business overseas, and asset management services business which provides financial products information. “Biotechnology, Healthcare & Medical Informatics Business” The Biotechnology, Healthcare & Medical Informatics Business represents development and distribution of pharmaceutical products, health foods, and cosmetics with 5-aminolevulinic acid (ALA*), a kind of amino acid which exists in vivo, research and development of antibody drugs and nucleic acid medicine in the field of cancer and immunology, the digitization of medical and health information, providing solutions and services that promote and the use of medical big data, and medical finance. “Others” includes the digital asset-related business, the real estate business, the renewable energy business and other businesses, but they did not meet the quantitative criteria to be defined as reportable segments for the fiscal year ended March 31, 2022. “Elimination or Corporate” includes profit or loss that is not allocated to certain business segments and the elimination of the inter-company transactions within the Group, at a price based on the actual market price. 13 The following represents segment information of the Group: SBI Estate Finance Co., Ltd. and SBI Guarantee Co., Ltd., which were included in the Asset Management Business until the previous reporting period, are now included in the Financial Services Business beginning with the six months ended September 30, 2021. Consequently, segment information for the year ended March 31, 2021, is restated in accordance with the new basis of segmentation. Also, Shinsei Bank, Limited is included in the Financial Services Business beginning with the nine months ended December 31, 2021. 14 For the year ended March 31, 2021FinancialServicesBusinessAssetManagementBusinessBiotechnology,Healthcare &MedicalInformaticsBusinessTotalOthersEliminationConsolidatedTotalMillions ofYenMillions ofYenMillions ofYenMillions ofYenMillions ofYenMillions ofYenMillions ofYenRevenue314,159205,8715,627525,65721,733(6,245)541,145Profit (loss) beforeincome tax expense86,38684,188(8,630)161,944(10,562)(11,002)140,380For the year ended March 31, 2022FinancialServicesBusinessAssetManagementBusinessBiotechnology,Healthcare &MedicalInformaticsBusinessTotalOthersEliminationConsolidatedTotalMillions ofYenMillions ofYenMillions ofYenMillions ofYenMillions ofYenMillions ofYenMillions ofYenRevenue396,179317,8319,920723,93044,293(4,605)763,618Profit (loss) beforeincome tax expense282,924165,962(11,845)437,041(11,990)(12,327)412,7242. Revenue (Note 1) Interest income arising from loans and bonds in the banking and securities businesses. (Note 2) Interest income arising from bonds in the banking and insurance businesses. 3. Earnings per Share The basic and diluted earnings per share attributable to owners of the Company are calculated based on the following information. 15 Fiscal year endedMarch 31, 2021Fiscal year endedMarch 31, 2022Millions of yenMillions of yenFinancial incomeInterest incomeIncome arising from financial assets measured atamortized cost (Note 1)142,628208,079Income arising from debt instruments measured atFVTOCI (Note 2)7361,340Income arising from financial assets measured at FVTPL133,532173,744Income arising from financial liabilities designated at FVTPL-5,475Others5768,331Total financial income277,472396,969Revenue arising on insurance contracts96,301112,630Revenue from contracts with customersRevenue from rendering of services105,431130,403Revenue from sales of goods14,89837,939Others47,04385,677Total revenue541,145763,618Fiscal year endedMarch 31, 2021Fiscal year endedMarch 31, 2022Millions of yenMillions of yenEarningsProfit attributable to owners of the Company81,098366,854Dilutive effect: Convertible bonds664757Profit attributable to owners of the Companyafter dilutive effect81,762367,611SharesSharesSharesBasic weighted average number of ordinaryshares238,676,048244,805,985Dilutive effect: Stock options2,244,0402,256,409Dilutive effect: Convertible bonds34,445,61738,816,665Weighted average number of ordinary sharesafter the dilutive effect275,365,705285,879,059Earnings per share attributable to owners ofthe CompanyYenYenBasic339.781,498.55Diluted296.921,285.904. Events after the Reporting Period There was no significant event after the reporting period. 5. Other Information The Group conducted a Tender Offer for the Shares of Shinsei Bank, Limited (the “Target Company”) to establish and reinforce a business alliance relationship between the Group and the Target Company. Based on the results of the Tender Offer, the Target Company became a consolidated subsidiary of the Company as of December 17, 2021 (the commencement date of settlement for the Tender Offer). As a result of the above business combination, total assets increased by ¥10,260,501 million in the Consolidated Statement of Financial Position, and a gain on bargain purchase of ¥263,754 million was recognized in the Consolidated Statement of Income. The loss recognized in the Consolidated Statement of Income from the acquisition date to the end of the reporting period of the Target Company was ¥56,421 million. This was mainly due to the recognition of expected credit losses on loans. With respect to the above business combination, the initial accounting for the acquired identifiable assets, liabilities assumed, non-controlling interests and gain on bargain purchase has not been completed, and the measurement has been made on a provisional basis based on currently available information, since it takes time to organize and analyze information mainly on loans, unlisted stocks, and customer deposits for banking business. 16